Risultati della ricerca - Henk‐Jan Guchelaar

Raffina i risultati
  1. 1
    Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients

    Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients di Romy Mosch, Henk‐Jan Guchelaar

    Pubblicazione 2022
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  2. 2
    The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms

    The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms di Hendrikus Bernhard Bouwman, Henk‐Jan Guchelaar

    Pubblicazione 2024
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  3. 3
    Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis

    Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis di Judith A.M. Wessels, T. Huizinga, Henk‐Jan Guchelaar

    Pubblicazione 2007
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  4. 4
    Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands

    Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands di Paul CD Bank, Jesse J. Swen, Henk‐Jan Guchelaar

    Pubblicazione 2019
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  5. 5
    Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines

    Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines di Lisanne E. N. Manson, Jesse J. Swen, Henk‐Jan Guchelaar

    Pubblicazione 2020
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  6. 6
    Clinical development of gene- and cell-based therapies: overview of the European landscape

    Clinical development of gene- and cell-based therapies: overview of the European landscape di Sofieke de Wilde, Henk‐Jan Guchelaar, Maarten L. Zandvliet, Pauline Meij

    Pubblicazione 2016
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  7. 7
    Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time

    Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time di Emma C. Hulshof, Maarten J. Deenen, Henk‐Jan Guchelaar, Hans Gelderblom

    Pubblicazione 2020
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  8. 8
    Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review

    Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review di Sylvia D. Klomp, Martijn L. Manson, Henk‐Jan Guchelaar, Jesse J. Swen

    Pubblicazione 2020
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  9. 9
    Technologies for Pharmacogenomics: A Review

    Technologies for Pharmacogenomics: A Review di Maaike van der Lee, Marjolein Kriek, Henk‐Jan Guchelaar, Jesse J. Swen

    Pubblicazione 2020
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  10. 10
    Applying Next-Generation Sequencing Platforms for Pharmacogenomic Testing in Clinical Practice

    Applying Next-Generation Sequencing Platforms for Pharmacogenomic Testing in Clinical Practice di Alireza Tafazoli, Henk‐Jan Guchelaar, Wojciech Miltyk, Adam Krętowski, Jesse J. Swen

    Pubblicazione 2021
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  11. 11
    3D Printing of Pediatric Medication: The End of Bad Tasting Oral Liquids?—A Scoping Review

    3D Printing of Pediatric Medication: The End of Bad Tasting Oral Liquids?—A Scoping Review di Iris Lafeber, Elisabeth J. Ruijgrok, Henk‐Jan Guchelaar, Kirsten J. M. Schimmel

    Pubblicazione 2022
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  12. 12
    Concordance of Predictive Markers for EGFR Inhibitors in Primary Tumors and Metastases in Colorectal Cancer: A Review

    Concordance of Predictive Markers for EGFR Inhibitors in Primary Tumors and Metastases in Colorectal Cancer: A Review di Jara M. Baas, L. L. Krens, Henk‐Jan Guchelaar, Hans Morreau, Hans Gelderblom

    Pubblicazione 2011
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  13. 13
    Lapatinib for Advanced or Metastatic Breast Cancer

    Lapatinib for Advanced or Metastatic Breast Cancer di Frans L. Opdam, Henk‐Jan Guchelaar, Jos H. Beijnen, Jan H.M. Schellens

    Pubblicazione 2012
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  14. 14
    Medical education in pharmacogenomics—results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx)

    Medical education in pharmacogenomics—results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation pr... di Katja S. Just, Michael Steffens, Jesse J. Swen, George P. Patrinos, Henk‐Jan Guchelaar, Julia Stingl

    Pubblicazione 2017
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  15. 15
    The Risk of Cancer in Users of Statins

    The Risk of Cancer in Users of Statins di Matthijs R. Graaf, Annette B. Beiderbeck, Toine C. G. Egberts, Dick J. Richel, Henk‐Jan Guchelaar

    Pubblicazione 2004
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  16. 16
    Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?

    Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options? di Jonathan E. Knikman, Hans Gelderblom, Jos H. Beijnen, Annemieke Cats, Henk‐Jan Guchelaar, Linda M. Henricks

    Pubblicazione 2020
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  17. 17
    Liver and kidney function in patients with Covid‐19 treated with remdesivir

    Liver and kidney function in patients with Covid‐19 treated with remdesivir di Sylvia A. van Laar, Mark de Boer, Kim B. Gombert‐Handoko, Henk‐Jan Guchelaar, J. Zwaveling

    Pubblicazione 2021
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  18. 18
    Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case–control study

    Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case–control study di E.R. Koomen, Arjen Joosse, Ron M. C. Herings, M. K. Casparie, Henk‐Jan Guchelaar, Tamar Nijsten

    Pubblicazione 2008
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  19. 19
    Low literacy and written drug information: information-seeking, leaflet evaluation and preferences, and roles for images

    Low literacy and written drug information: information-seeking, leaflet evaluation and preferences, and roles for images di Mara M. van Beusekom, Petronella Grootens‐Wiegers, Mark Bos, Henk‐Jan Guchelaar, Jos M. van den Broek

    Pubblicazione 2016
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  20. 20
    The extent and effects of patient involvement in pictogram design for written drug information: a short systematic review

    The extent and effects of patient involvement in pictogram design for written drug information: a short systematic review di Mara M. van Beusekom, Anne H. Kerkhoven, Mark Bos, Henk‐Jan Guchelaar, Jos M. van den Broek

    Pubblicazione 2018
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: